235 related articles for article (PubMed ID: 17274039)
1. Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: results from a multi-center, randomized, active controlled trial.
Trenkwalder C; Benes H; Grote L; Happe S; Högl B; Mathis J; Saletu-Zyhlarz GM; Kohnen R;
Mov Disord; 2007 Apr; 22(5):696-703. PubMed ID: 17274039
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of cabergoline in restless legs syndrome: a placebo-controlled study with polysomnography (CATOR).
Oertel WH; Benes H; Bodenschatz R; Peglau I; Warmuth R; Happe S; Geisler P; Cassel W; Leroux M; Kohnen R; Stiasny-Kolster K
Neurology; 2006 Sep; 67(6):1040-6. PubMed ID: 16931508
[TBL] [Abstract][Full Text] [Related]
3. Treatment of idiopathic restless legs syndrome (RLS) with the D2-agonist cabergoline--an open clinical trial.
Stiasny K; Röbbecke J; Schüler P; Oertel WH
Sleep; 2000 May; 23(3):349-54. PubMed ID: 10811379
[TBL] [Abstract][Full Text] [Related]
4. Effective cabergoline treatment in idiopathic restless legs syndrome.
Stiasny-Kolster K; Benes H; Peglau I; Hornyak M; Holinka B; Wessel K; Emser W; Leroux M; Kohnen R; Oertel WH
Neurology; 2004 Dec; 63(12):2272-9. PubMed ID: 15623686
[TBL] [Abstract][Full Text] [Related]
5. Ropinirole in patients with restless legs syndrome and baseline IRLS total scores ≥ 24: efficacy and tolerability in a 26-week, double-blind, parallel-group, placebo-controlled study followed by a 40-week open-label extension.
Giorgi L; Asgharian A; Hunter B
Clin Ther; 2013 Sep; 35(9):1321-36. PubMed ID: 23938061
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Parkinson's disease and restless legs syndrome with cabergoline, a long-acting dopamine agonist.
Porter MC; Appiah-Kubf LS; Chaudhuri KR
Int J Clin Pract; 2002; 56(6):468-74. PubMed ID: 12166546
[TBL] [Abstract][Full Text] [Related]
7. One-year treatment with standard and sustained-release levodopa: appropriate long-term treatment of restless legs syndrome?
Trenkwalder C; Collado Seidel V; Kazenwadel J; Wetter TC; Oertel W; Selzer R; Kohnen R
Mov Disord; 2003 Oct; 18(10):1184-9. PubMed ID: 14534925
[TBL] [Abstract][Full Text] [Related]
8. Augmentation in restless legs syndrome is associated with low ferritin.
Trenkwalder C; Högl B; Benes H; Kohnen R
Sleep Med; 2008 Jul; 9(5):572-4. PubMed ID: 17921065
[TBL] [Abstract][Full Text] [Related]
9. Validation of the Augmentation Severity Rating Scale (ASRS): a multicentric, prospective study with levodopa on restless legs syndrome.
García-Borreguero D; Kohnen R; Högl B; Ferini-Strambi L; Hadjigeorgiou GM; Hornyak M; de Weerd AW; Happe S; Stiasny-Kolster K; Gschliesser V; Egatz R; Cabrero B; Frauscher B; Trenkwalder C; Hening WA; Allen RP
Sleep Med; 2007 Aug; 8(5):455-63. PubMed ID: 17543579
[TBL] [Abstract][Full Text] [Related]
10. Low-dose pramipexole in the management of restless legs syndrome. An open label trial.
Stiasny-Kolster K; Oertel WH
Neuropsychobiology; 2004; 50(1):65-70. PubMed ID: 15179023
[TBL] [Abstract][Full Text] [Related]
11. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of pramipexole in Japanese patients with primary restless legs syndrome: A polysomnographic randomized, double-blind, placebo-controlled study.
Inoue Y; Hirata K; Kuroda K; Fujita M; Shimizu T; Emura N; Uchimura N; Kagimura T; Sha K; Nozawa T
Sleep Med; 2010 Jan; 11(1):11-6. PubMed ID: 19962941
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of sumanirole in restless legs syndrome: a phase II, randomized, double-blind, placebo-controlled, dose-response study.
Garcia-Borreguero D; Winkelman J; Adams A; Ellis A; Morris M; Lamb J; Layton G; Versavel M;
Sleep Med; 2007 Mar; 8(2):119-27. PubMed ID: 17239657
[TBL] [Abstract][Full Text] [Related]
14. Dopamine agonists for restless legs syndrome.
Scholz H; Trenkwalder C; Kohnen R; Riemann D; Kriston L; Hornyak M
Cochrane Database Syst Rev; 2011 Mar; 2011(3):CD006009. PubMed ID: 21412893
[TBL] [Abstract][Full Text] [Related]
15. What treatment works best for restless legs syndrome? Meta-analyses of dopaminergic and non-dopaminergic medications.
Hornyak M; Scholz H; Kohnen R; Bengel J; Kassubek J; Trenkwalder C
Sleep Med Rev; 2014 Apr; 18(2):153-64. PubMed ID: 23746768
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of pramipexole in chinese patients with restless legs syndrome: results from a multi-center, randomized, double-blind, placebo-controlled trial.
Ma JF; Wan Q; Hu XY; Sun SG; Wang WZ; Zhao ZX; Wang YJ; Liu CF; Li JM; Jiang YP; Chen SD
Sleep Med; 2012 Jan; 13(1):58-63. PubMed ID: 22137119
[TBL] [Abstract][Full Text] [Related]
17. Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial.
Montplaisir J; Karrasch J; Haan J; Volc D
Mov Disord; 2006 Oct; 21(10):1627-35. PubMed ID: 16874755
[TBL] [Abstract][Full Text] [Related]
18. Long-term open-label study of pramipexole in patients with primary restless legs syndrome.
Inoue Y; Kuroda K; Hirata K; Uchimura N; Kagimura T; Shimizu T
J Neurol Sci; 2010 Jul; 294(1-2):62-6. PubMed ID: 20451927
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of ropinirole in patients with restless legs syndrome and a baseline IRLS total score > or = 24 points--data from the ropinirole clinical trial programme.
Giorgi L; Ritchie SY; Kirsch JM
Curr Med Res Opin; 2006 Oct; 22(10):1867-77. PubMed ID: 17022844
[TBL] [Abstract][Full Text] [Related]
20. Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome.
Trenkwalder C; Stiasny-Kolster K; Kupsch A; Oertel WH; Koester J; Reess J
Mov Disord; 2006 Sep; 21(9):1404-10. PubMed ID: 16755554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
